The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 26, 2016
Filed:
Oct. 16, 2008
Anand Khedkar, Karnataka, IN;
Sharath Kumar Mallapura Rangappa, Karnataka, IN;
Ramesh Subramani, Tamil Nadu, IN;
Nitesh Dave, Karnataka, IN;
Devesh Radhakrishnan, Maharashtra, IN;
Sundaresh Shankar, Karnataka, IN;
Sudheer Chivukula, Karnataka, IN;
Ranjith Ramakrishna, Karnataka, IN;
Shanmugam Thandava Murthy, Tamil Nadu, IN;
Harish Venkatraman Pai, Karnataka, IN;
Nilanjan Sengupta, Karnataka, IN;
Ramakrishnan Melarkode, Karnataka, IN;
Harish Iyer, Karnataka, IN;
Anand Khedkar, Karnataka, IN;
Sharath Kumar Mallapura Rangappa, Karnataka, IN;
Ramesh Subramani, Tamil Nadu, IN;
Nitesh Dave, Karnataka, IN;
Devesh Radhakrishnan, Maharashtra, IN;
Sundaresh Shankar, Karnataka, IN;
Sudheer Chivukula, Karnataka, IN;
Ranjith Ramakrishna, Karnataka, IN;
Shanmugam Thandava Murthy, Tamil Nadu, IN;
Harish Venkatraman Pai, Karnataka, IN;
Nilanjan Sengupta, Karnataka, IN;
Ramakrishnan Melarkode, Karnataka, IN;
Harish Iyer, Karnataka, IN;
BIOCON LIMITED, , IN;
Abstract
The invention relates to improvised pharmaceutical compositions permitting ingestion via oral delivery of proteins/peptides or their conjugates, and/or cation-insulin conjugate complexes demonstrating desirable pharmacokinetic profiles and potency in efficacy models of diabetes in dogs and humans. A preferred formulation comprises 0.01%-20% w/w of insulin, insulin compound conjugates and/or cation insulin conjugates, 10%-60% w/w of one or more fatty acid components selected from saturated or unsaturated C4-C12 fatty acids and/or salts of such fatty acids and additionally contains optimal amounts of other pharmaceutically suitable polymer excipients which permit improved solubility, dissolution rate and effective bioavailability of poorly water soluble compositions and consistent in-vivo release profiles upon scalability during manufacture. A further aspect of the invention features the process of preparing the aforesaid formulations.